Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases ...
Advicenne’s shares rose 6% to 1.76 euros this morning, on the news it has obtained both marketing authorization (MA) and ...
Advicenne SA (ALDVI.PA), a French pharmaceutical company focused on rare kidney diseases, announced Monday that the U.S. Food ...
Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases ...
French nephrology specialist Advicenne has announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Sibnayal (ADV7103), a fixed combination ...
Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare ...
Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases ...
Sibnayal® sales rose 36.6% to €3.01m2025 Royalties are estimated at €1m, double the amount for 2024End-markets estimated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results